Ondansetron for the Management of Atrial Fibrillation

Atrial Fibrillation Clinical Trial

Official title:

Inhibition of Small Conductance Calcium-Activated Potassium Current: A New Therapeutic Approach for Atrial Fibrillation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05844501
• Other study ID #: 16581
• Secondary ID: 22TPA964193
• Status: Recruiting
• Phase: Phase 4
• Start date: July 1, 2024
• Est. completion date: December 31, 2027

Study information

• Verified date: June 2024
• Source: Indiana University
• Contact: James E Tisdale, PharmD
• Phone: 317-880-5418
• Email: jtisdale[@]purdue.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

"Afib" is a common irregular heartbeat. Afib can cause stroke, blood clots, dementia and death. Medicines used to treat Afib often do not work well and can cause serious side effects. Clinicians need medicines that work better for Afib. Medicines for Afib work by blocking a current in the heart called a potassium current. There is a newer potassium current called IKas that can contribute to Afib. A medicine called ondansetron is used to keep people with cancer from getting sick to their stomach and throwing up. The investigators have found that ondansetron blocks IKas, and the investigators think that this means that ondansetron may work well to treat Afib. So, in this study the investigators want to find out if ondansetron can: 1) Reduce the amount of time that people have Afib, and 2) Slow down the heart rate when people have Afib. The investigators will study 80 people who come to the hospital to have a small electric shock to stop their Afib. After the shock, these patients will be assigned by chance (like flipping a coin) to one of two groups: ondansetron 8 mg by mouth twice daily or a sugar pill (placebo). The people in the study will not know whether they are receiving ondansetron or placebo. The ondansetron or placebo will be started within 7 days after the electric shock. The investigators will find out if ondansetron reduces the percentage of time that people are in Afib. Also, the investigators will find out if ondansetron slows the heart rate while people are having Afib. The investigators will compare the people in the study who take ondansetron with the people in the study who take placebo. This research will help the investigators to find out if ondansetron can be used as a medicine for people who have Afib.

Description:

Atrial fibrillation (AF) is a common arrhythmia associated with symptoms, stroke, systemic embolism, heart failure, dementia, and mortality. Guideline-recommended strategies for conversion to and maintenance of sinus rhythm (SR) and ventricular rate (VR) control are of limited efficacy and/or are poorly tolerated. There is a critical need for safer, more effective alternatives for AF drug therapy. The apamin-sensitive small-conductance calcium-activated potassium (SK) ion current (IKas) is important for repolarization in the atria and pulmonary vein muscle sleeves. IKas also contributes to sinoatrial and AV node electrophysiology. Therefore, IKas may be a target for rhythm and rate control in AF. Evidence suggests: 1) IKas plays an important role in the mechanism of AF, 2) The antiemetic agent ondansetron at therapeutic concentrations is a potent IKas inhibitor, and 3) Ondansetron is a cardiac-selective IKas inhibitor. Thus, the investigators hypothesize that ondansetron is effective for rhythm and rate control in patients with AF. Specific Aim 1: Determine the efficacy and safety of ondansetron for reducing AF burden. This aim will be achieved via a prospective, randomized, double-blind placebo-controlled study in patients with AF (n=80). Patients with persistent AF scheduled to undergo elective direct current cardioversion (DCC) will be randomized to oral ondansetron 8 mg twice daily (n=40) or matching placebo (n=40) for 28 days. The ondansetron/placebo will be initiated within 7 days following the DCC procedure. Continuous ECG recording will be performed using 2 consecutive adhesive skin patch ECG monitors, which provide 14-days of continuous recording. The primary outcome measure will be AF burden (percentage of time in AF). Specific Aim 2: Determine the efficacy and safety of ondansetron for VR control in AF. The effect of ondansetron versus placebo on VR control will be assessed. Primary outcome measures will be mean daily heart rates in AF on days 7, 14, 21 and 28 days following initiation of ondansetron/placebo.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 31, 2027
• Est. primary completion date: December 31, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Men and women 18-100 years of age

• Persistent ECG-verified AF and/or atrial flutter requiring elective conversion to SR

• Receiving guideline-recommended anticoagulation (if CHA2DS2-VASc score is 0 (men) or 1 (women), anticoagulation can be omitted)

Exclusion Criteria:

• Women of childbearing potential

• Subject reported syncope of unknown origin within the previous 6 months

• Diagnosis of active thyrotoxicosis

• Diagnosis AF from reversible noncardiac causes

• Diagnosis of acutely decompensated heart failure

• Left ventricular ejection fraction less than or equal to 20%

• New York Heart Association class IV heart failure

• Diagnosis of severe liver disease (Child-Pugh score greater than or equal to 10)

• Cardiac surgery (preceding 2 months)

• Not receiving anticoagulation due to contraindications (as determined by treating physician and recorded in the medical record)

• Pretreatment QRS > 180 ms, QTc > 450 ms within two weeks of screening visit

• Heart rate < 50 beats per minute in SR

• Diagnosis of hypotension

• Diagnosis of Wolff-Parkinson-White syndrome

• Previous ondansetron hypersensitivity or serotonin syndrome

• Diagnosis of phenylketonuria

• Diagnosis of congenital long QT syndrome

• Concomitant therapy with both beta-blockers and a nondihydropyridine CCB

• History of drug-induced torsades de pointes or QTc prolongation

• Concomitant therapy with QTc-prolonging medications (www.crediblemeds.org), except amiodarone and propafenone

• Concomitant therapy with serotonergic drugs (selective serotonin reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, mirtazapine, lithium, tramadol), apomorphine, phenytoin, carbamazepine, oxcarbazepine, rifampin.

• Left ventricular ejection fraction < 20% and those with NYHA class IV heart failure with reduced ejection fraction (confirmed by diagnosis or echocardiogram within 6 months of enrollment in screening)

• Patients with pre-existing allergies to adhesives

• Patients with neuromuscular stimulators

Related Conditions & MeSH terms

• Atrial Fibrillation

Intervention

Drug:
• Ondansetron 8mg
Ondansetron 8 mg orally twice daily for 28 days
• Placebo
Matched placebo orally twice daily for 28 days

Locations

Country	Name	City	State
United States	Indiana Clinical Research Center	Indianapolis	Indiana
United States	Indiana University Health Methodist Hospital	Indianapolis	Indiana
United States	Purdue University	Indianapolis	Indiana

Sponsors (3)

Lead Sponsor	Collaborator
Indiana University	American Heart Association, Purdue University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Atrial fibrillation burden	Burden of atrial fibrillation, defined as overall percentage of time in atrial fibrillation.	Total duration of study (28 days)
Primary	Ventricular rate control	Maximum heart rate while in atrial fibrillation	7 days after initiation of ondansetron/placebo
Primary	Ventricular rate control	Maximum heart rate while in atrial fibrillation	14 days after initiation of ondansetron/placebo
Primary	Ventricular rate control	Maximum heart rate while in atrial fibrillation	21 days after initiation of ondansetron/placebo
Primary	Ventricular rate control	Maximum heart rate while in atrial fibrillation	28 days after initiation of ondansetron/placebo
Secondary	Proportion of patients in sinus rhythm	Proportion of patients in sinus rhythm at 28 days after initiation of ondansetron/placebo	28 days after initiation of ondansetron/placebo
Secondary	Time to atrial fibrillation recurrence	Time to atrial fibrillation recurrence after electrical cardioversion	28 days after scheduled electrical cardioversion
Secondary	Adverse effects	Adverse effects associated with ondansetron or placebo	During the 28 days of treatment with ondansetron or placebo